Other substances

Etoposide

A DNA synthesis inhibitor.

Phase of research

Potential treatment - theoretical effect

How it helps

Antiviral

Drug status

Experimental

Supporting references

Contradictory references

AI-suggested references

Clinical trials

General information

Etoposide on PubChem

Structure image - Etoposide

C[C@@H]1OC[C@@H]2[C@@H](O1)[C@@H]([C@H]([C@@H](O2)O[C@H]3[C@H]4COC(=O)[C@@H]4[C@@H](C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)O)OC)O)O

Supporting references

Link	Tested on	Impact factor	Notes	Publication date
Repurposing approved drugs as potential inhibitors of 3CL-protease of SARS-CoV-2: Virtual screening and structure based drug design 3CLpro Small molecule In silico Screening	in silico	1.85	Predicted to inhibit SARS-CoV-2 3C-like protease.	Jul/31/2020

AI-suggested references

Link	Publication date
Community Birth: The Value of Collaboration.	Oct/29/2020
Cyclophosphamide plus etoposide is a safe and effective mobilization regimen in patients with multiple myeloma.	Dec/23/2021
Safety and efficacy of a dose-dense short-term therapy in patients with MYC-translocated aggressive lymphoma.	Jan/19/2022
Topoisomerase 2 inhibitor etoposide promotes interleukin-10 production in LPS-induced macrophages via upregulating transcription factor Maf and activating PI3K/Akt pathway.	Oct/07/2020
Ruxolitinib as adjunctive therapy for secondary hemophagocytic lymphohistiocytosis: A case series.	Feb/17/2021
Etoposide-based therapy for severe forms of COVID-19	May/25/2021
Molecular docking and dynamic simulations of Cefixime, Etoposide and Nebrodenside A against the pathogenic proteins of SARS-CoV-2.	Aug/13/2021
Etoposide as Salvage Therapy for Cytokine Storm Due to Coronavirus Disease 2019.	Sep/12/2020
Complete remission of stage IV sinonasal small cell neuroendocrine carcinoma: A case report.	Dec/23/2021
Feasibility and safety of outpatient administration of ifosfamide and etoposide for pediatric patients with Ewing sarcoma in a resource-limited setting amid the COVID-19 pandemic	Jan/14/2021
Case Report: Successful Treatment of Five Critically Ill Coronavirus Disease 2019 Patients Using Combination Therapy With Etoposide and Corticosteroids	Sep/23/2021
Four Cycles of Etoposide plus Cisplatin for Patients with Good-Risk Advanced Germ Cell Tumors	Mar/12/2021
Computational estimation of potential inhibitors from known drugs against the main protease of SARS-CoV-2	May/12/2021
Oral etoposide combined with oral arsenic plus retinoic acid for two cases with newly diagnosed high-risk acute promyelocytic leukemia during COVID19 pandemic.	Jul/14/2021
Vinblastine monotherapy induction prior to radiotherapy for patients with intracranial germinoma during the COVID-19 pandemic	Oct/13/2021

Clinical trials

ID	Title	Status	Phase	Start date	Completion date
NCT04356690	Etoposide in Patients With COVID-19 Infection	Active, not recruiting	Phase 2	May/08/2020	Jun/01/2022
Alternative id - H-40102 Interventions - Drug: Etoposide Study type - Interventional Study results - No Results Available Locations - Boston Medical Center, Boston, Massachusetts, United States Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Supportive Care Enrollment - 8 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Change in pulmonary status\|Change in ferritin levels\|Change in C-reactive protein levels\|Change in d-dimer levels\|Change in white blood cell count\|Incidence of serious adverse events\|Overall survival\|Length of hospitalization\|Duration of ventilation\|Ventilator free days\|Improvement in arterial oxygen partial pressure (PaO2) to fractional inspired oxygen (FiO2)